Axon Enterprise (AXON) reached $407.8 at the closing of the latest trading day, reflecting a -1.34% change compared to its last close.

Adirondack Trust Co. lifted its position in Axon Enterprise, Inc (NASDAQ:AXON - Free Report) by 8,341.7% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 21,864 shares of the biotechnology

View the basic AXON option chain and compare options of Axon Enterprise, Inc. on Yahoo Finance.

Vea la cadena de opciones básica de AXON y compare las opciones de Axon Enterprise, Inc. en Yahoo Finance.

View the basic AXON option chain and compare options of Axon Enterprise, Inc. on Yahoo Finance.

Krilogy Financial LLC grew its stake in shares of Axon Enterprise, Inc (NASDAQ:AXON - Free Report) by 1,337.9% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 18,980 shares of the biotechnology company

Recently, Zacks.com users have been paying close attention to Axon (AXON). This makes it worthwhile to examine what the stock has in store.

Axon Enterprise (AXON) reached $407.8 at the closing of the latest trading day, reflecting a -1.34% change compared to its last close.

First Financial Corp IN bought a new position in Axon Enterprise, Inc (NASDAQ:AXON - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 7,058 shares of the biotechnology company

Avior Wealth Management LLC boosted its position in Axon Enterprise, Inc (NASDAQ:AXON - Free Report) by 1,837.4% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 34,873 shares of the biotechno

NorthCrest Asset Manangement LLC increased its position in shares of Axon Enterprise, Inc (NASDAQ:AXON - Free Report) by 16,798.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 501,720 shares of the biotechnolog